The present disclosure relates to methods for characterizing and diagnosing dental diseases. In particular, the present disclosure relates to methods for characterizing and diagnosing dental disease (e.g., gingivitis and periodontal disease) based on levels of AI-2 in oral fluids and plaque.

A system and method for assessing global wellness and developing a maintenance/treatment program are provided, wherein a plurality of data sources are compiled, including, at minimum (a) a subject's medical, dental and family histories, and (b) a body fluid sample (e.g. an oral swab or saliva) for detecting and determining levels of one or more biomarkers, and wherein these data are used to assess the subject's global health and wellness landscape, which is then compared to a reference/ideal wellness landscape, and the comparison used to design a maintenance therapy/treatment plan.

Methods and kits for determining the presence or severity of oral inflammation, such as gingivitis or periodontitis wherein the determination method comprises: (a) obtaining a test sample of oral material from said subject; (b) determining the amount of polymorphonuclear neutrophil indicator substance in said test sample; and (c) comparing the amount of polymorphonuclear neutrophil indicator substance in the test sample to a control sample.

Procedures are provided to evaluate the effectiveness of slow-acting antibacterial agents such as metal salts on reduction of bacterial oral biofilm. In the modified process, the exposure time of the agent is increased from the usual 3 minutes to 7-15 minutes, e.g., about 10 minutes, and the duration increased to 5-12 days, e.g., about 8 days instead of the conventional 3 days.

Herein is reported a method for determining the binding affinity of the binding sites of a bivalent full length antibody of the human IgG1 subclass to a homo-multimeric antigen comprising the steps of i) incubating a mixture comprising the antibody and a polypeptide that is derived from lysine-gingipain of Porphyromonas gingivalis at a pH of from pH 7.5 to pH 8.5, in the presence of a reducing agent, at a temperature of from 30 C. to 42 C., for time of from 10 min. to 240 min. to cleave the antibody into Fabs and Fc-region, and ii) determining the binding affinity of the Fabs of the antibody for its antigen using a surface plasmon resonance method by directly applying the incubated reaction mixture obtained in the previous step in the surface plasmon resonance method and therewith determining the binding affinity of the binding sites of the bivalent full length antibody of the human IgG1 subclass.

A system and method for assessing global wellness and developing a maintenance/treatment program are provided, wherein a plurality of data sources are compiled, including, at minimum (a) a subject's medical, dental and family histories, and (b) a body fluid sample (e.g. an oral swab or saliva) for detecting and determining levels of one or more biomarkers, and wherein these data are used to assess the subject's global health and wellness landscape, which is then compared to a reference/ideal wellness landscape, and the comparison used to design a maintenance therapy/treatment plan.

Antigen-binding molecules (ABMs) that bind to Porphyromonas gingivalis are described. The ABMs may be human or humanized ABMs. The ABMs find use in treating infections involving P. gingivalis, such as periodontal disease. Also provided are methods of treating or preventing a disorder or disease by administering the ABM.

A kit for detecting an inflammation level of an oral cavity based on a biomarker indicative of inflammation, the kit comprising at least one rinsing substance; a cup sized to contain a predetermined amount of at least one rinsing substance; a colourimetric reference corresponding to a predetermined inflammation level, and a colourimetric indicator reactive to the biomarker in the at least one rinsing substance consistently with the colourimetric reference.

A kit for detecting an inflammation level of an oral cavity based on a biomarker indicative of inflammation, the kit comprising at least one rinsing substance; a cup sized to contain a predetermined amount of at least one rinsing substance; a colourimetric reference corresponding to a predetermined inflammation level, and a colourimetric indicator reactive to the biomarker in the at least one rinsing substance consistently with the colourimetric reference.

Present invention relates to the in vitro use of the level or concentration in a salivary or breath sample of bacteria belonging to the Alloprevotella, Prevotella, Campylobacter, Rothia, Catonella, Porphyromona, Fretibacterium genus, or any combination thereof, for the diagnosis of carcinomas or epidermoid cancers, especially epidermoid cancer of the head and neck, in a patient, or to obtain useful data that allow such a diagnosis.